| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RPTX | Common Shares | Sale | -$297K | -9.05K | -0.22% | $32.80 | 4.14M | Jun 8, 2021 | See Footnote | F1, F2, F3, F4 |
| transaction | RPTX | Common Shares | Sale | -$573K | -17.2K | -0.41% | $33.41 | 4.12M | Jun 8, 2021 | See Footnote | F1, F5, F6, F7 |
| transaction | RPTX | Common Shares | Sale | -$374K | -10.9K | -0.26% | $34.42 | 4.11M | Jun 9, 2021 | See Footnote | F1, F8, F9, F10 |
| transaction | RPTX | Common Shares | Sale | -$848K | -24.4K | -0.59% | $34.79 | 4.08M | Jun 9, 2021 | See Footnote | F1, F11, F12, F13 |
| Id | Content |
|---|---|
| F1 | Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. |
| F2 | The shares were sold as follows: 3,852 by MPM BioVentures 2014, L.P. ("BV 2014"), 133 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,060 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.16 to $33.145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F4 | The shares are held as follows: 2,144,411 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 73,811 by AM BV2014 and 1,781,315 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| F5 | The shares were sold as follows: 7,308 by BV 2014, 251 by AM BV2014 and 9,596 by UBS Oncology. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.16 to $33.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F7 | The shares are held as follows: 2,137,103 by BV 2014, 135,843 by BV 2014(B), 73,560 by AM BV2014 and 1,771,719 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| F8 | The shares were sold as follows: 4,627 by BV 2014, 158 by AM BV2014 and 6,077 by UBS Oncology. |
| F9 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.66 to $34.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F10 | The shares are held as follows: 2,132,476 by BV 2014, 135,843 by BV 2014(B), 73,402 by AM BV2014 and 1,765,642 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| F11 | The shares were sold as follows: 10,379 by BV 2014, 359 by AM BV2014 and 13,630 by UBS Oncology. |
| F12 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.69 to $35.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F13 | The shares are held as follows: 2,122,097 by BV 2014, 135,843 by BV 2014(B), 73,043 by AM BV2014 and 1,752,012 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |